Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) President Cam Gallagher Sells 10,000 Shares
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) President Cam Gallagher Sells 10,000 Shares
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 10,000 shares of the company's stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $21.02, for a total transaction of $210,200.00. Following the completion of the sale, the president now directly owns 362,011 shares in the company, valued at approximately $7,609,471.22. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
纳斯达克(代码:ZNTL-GET Rating)总裁在一笔日期为1月5日星期四的交易中出售了10,000股该公司股票。该股以21.02美元的平均价格出售,总成交金额为210,200.00美元。出售完成后,总裁现在直接拥有公司362,011股,价值约7,609,471.22美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接.
Cam Gallagher also recently made the following trade(s):
卡姆·加拉格尔最近还进行了以下交易:
- On Tuesday, November 15th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $22.77, for a total transaction of $284,625.00.
- On Monday, November 7th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $23.67, for a total transaction of $295,875.00.
- On Monday, October 17th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $23.51, for a total transaction of $293,875.00.
- 11月15日,星期二,卡姆·加拉格尔出售了12,500股Zentalis制药公司的股票。该股以22.77美元的平均价格出售,总成交金额为284,625.00美元。
- 11月7日,星期一,卡姆·加拉格尔出售了12,500股Zentalis制药公司的股票。该股以23.67美元的平均价格出售,总成交金额为295,875.00美元。
- 10月17日,星期一,卡姆·加拉格尔出售了12,500股Zentalis制药公司的股票。该股以23.51美元的平均价格出售,总成交金额为293,875.00美元。
Zentalis Pharmaceuticals Stock Performance
Zentaris制药类股表现
Zentalis Pharmaceuticals stock traded up $0.23 during trading hours on Thursday, reaching $21.27. 960,828 shares of the company's stock traded hands, compared to its average volume of 838,876. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $17.33 and a fifty-two week high of $76.00. The firm's 50 day moving average is $21.00 and its 200-day moving average is $24.48.
在周四的交易中,Zentalis制药公司的股票上涨了0.23美元,达到21.27美元。该公司股票成交量为960,828股,而其平均成交量为838,876股。Zentalis PharmPharmticals,Inc.的股价为52周低点17.33美元,52周高点为76.00美元。该公司的50日移动均线切入位为21.00美元,200日移动均线切入位为24.48美元。
Institutional Inflows and Outflows
机构资金流入和流出
Analyst Ratings Changes
分析师评级发生变化
Several equities research analysts have recently weighed in on ZNTL shares. Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a report on Monday, November 14th. Morgan Stanley decreased their price objective on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 11th. UBS Group decreased their price objective on shares of Zentalis Pharmaceuticals to $52.00 in a report on Monday, November 21st. SVB Leerink decreased their price objective on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Finally, Wedbush decreased their price objective on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $46.56.
几位股票研究分析师最近纷纷买入ZNTL的股票。在11月14日周一的一份报告中,富国银行将Zentalis制药公司的股票目标价从52.00美元下调至46.00美元。在11月11日星期五的一份报告中,摩根士丹利将Zentalis制药公司的股票目标价从60.00美元下调至55.00美元,并对该股设定了“增持”评级。瑞银集团在11月21日星期一的一份报告中将Zentalis制药公司的股票目标价下调至52.00美元。SVB Leerink在11月10日(星期四)的一份报告中将Zentalis PharmPharmticals的股票目标价从42.00美元下调至27.00美元,并对该股设定了“跑赢大盘”的评级。最后,韦德布什在11月14日星期一的一份报告中将Zentalis制药公司的股票目标价从51.00美元下调至32.00美元,并对该股设定了“跑赢大盘”的评级。根据MarketBeat.com的数据,九位投资分析师对该股的评级为买入,该公司目前的普遍评级为买入,平均目标价为46.56美元。
About Zentalis Pharmaceuticals
关于Zentaris制药公司
(Get Rating)
(获取评级)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis制药公司是一家临床阶段的生物制药公司,专注于发现和开发用于治疗各种癌症的小分子疗法。它的主要候选产品包括WEE1的抑制剂ZN-c3,这是一种蛋白质酪氨酸激酶,正处于治疗晚期实体肿瘤的第二阶段临床试验;作为单一疗法治疗晚期实体肿瘤的第1/2阶段临床试验,以及正在进行的与铂耐药卵巢癌患者的联合化疗的1b阶段临床试验;以及肿瘤不可知的、可预测的生物标记物的第二阶段单一治疗试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
- Will Trade Desk Inc Bounce Off Its Support Line?
- Conagra Brands: Another Reason To Go Long Consumer Staples In 2023
- 免费获取StockNews.com关于Zentalis制药的研究报告(ZNTL)
- 为什么卡夫亨氏走得更高
- 这对今年德文能源的股价意味着什么?
- 蔚来股,这是底部吗?
- Trade Desk Inc.会从支撑线上反弹吗?
- 康尼格拉品牌:2023年做多消费品的另一个原因
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zentaris制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zentalis制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。